로그인

University of Maryland School of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center

2 ARTICLES PUBLISHED IN JoVE

Biology

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Karthika Natarajan^1,2, Yi Xie^1,3, Takeo Nakanishi⁴, Rebecca S. Moreci^5,6, Pancharatnam Jeyasuria⁷, Arif Hussain^1,3,8,9, Douglas D. Ross^{1,3,8,9,10,11}

¹Greenebaum Cancer Center, University of Maryland School of Medicine, ²Pharmaceutical Sciences, University of Maryland School of Pharmacy, ³Baltimore VA Medical Center, ⁴Membrane Transport and Biopharmaceutics, School of Pharmaceutical Sciences, Kanazawa University, ⁵Obstetrics, Gynecology and Reproductive Science, University of Pittsburgh, ⁶Magee Women's Research Institute, ⁷Obstetrics, Gynecology, Perinatal Research Branch (NICHD), Wayne State University School of Medicine, ⁸Medicine, University of Maryland School of Medicine, ⁹Pathology, University of Maryland School of Medicine, ¹⁰Pharmacology, University of Maryland School of Medicine, ¹¹Experimental Therapeutics, University of Maryland School of Medicine

With the murine ABC transporter Bcrp1 (Abcg2) as an example, in-silico protocols are presented to detect alternative promoter usage in genes expressed in mouse tissues, and to evaluate the functionality of the alternative promoters identified using reporter assays.

Medicine

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Adeel Kaiser¹, John G. Eley¹, Nasarachi E. Onyeuku¹, Stephanie R. Rice¹, Carleen C. Wright², Nathan E. McGovern², Megan Sank², Mingyao Zhu¹, Zeljko Vujaskovic¹, Charles B. Simone 2nd¹, Arif Hussain³

¹Department of Radiation Oncology, University of Maryland School of Medicine, ²Department of Radiation Oncology, University of Maryland Medical Center, ³Department of Medicine, University of Maryland School of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center

The fundamentals of radiation planning and delivery for proton therapy using prostate cancer as a model are presented. The application of these principles to other selected disease sites highlights how proton radiotherapy may enhance clinical outcomes for cancer patients.